OTLK - Outlook Therapeutics announces UK marketing authorization of its wet AMD treatment
2024-07-08 10:03:19 ET
More on Outlook Therapeutics
- Outlook Therapeutics: Worth A Good Strong Look After CRL
- Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market
- Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript
- Outlook gets EU approval for Lytenava for wet AMD
- Seeking Alpha’s Quant Rating on Outlook Therapeutics